ObesityOUTSTEP-1NCT07154238
Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.
An observational study of Obesity, run by Novo Nordisk A/S at 1 site in Germany.
Trial summary
The purpose of this study is to collect information for scientific research and to better understand the experiences of participants managing their weight. The study aims to collect valid responses through online interviews from participants. This study is a survey-based study without collection of laboratory data. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Obesity
- What is being tested?
- No treatment given
- How many people
- 2,546 participants
- Where
- 1 siteGermany
- Study dates
- 26 Sep 2025to 30 Sep 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: This study will collect quantitative and qualitative data from individuals treated with injectable semaglutide for weight management in real-world settings. The study will include two groups of participants: 1. Individuals who belong to or are recruited to an opt-in panel in the countries of interest and who have initiated injectable semaglutide for weight management. They will be classified according to the time when they first initiated treatment with injectable semaglutide for weight management. 2. HCPs who prescribe injectable semaglutide for weight management will be recruited from an existing opt-in panel in the countries of interest.
Who may be able to join
- For an eligible participant (individuals initiated on injectable semaglutide for weight management), all inclusion criteria must be answered "yes".
- Electronically provided consent obtained before any study-related activities can be completed.
- Age above or equal to 18 years at the time of providing informed consent.
- Reside in a participating country: Australia, Germany, United Arab Emirates (UAE) and Spain.
- Have been prescribed and initiated injectable semaglutide for weight management prior to study screening.
- For an eligible participant (HCPs), all inclusion criteria must be answered "yes".
Show all 13Show fewer
- Electronically provided consent obtained before any study-related activities can be completed.
- Practice in a participating country: Australia, Germany, UAE, and Spain.
- See at least 150 patients for any condition per month; priority given to those who treat at least 200 patients for any condition per month.
- Treat at least 10 adult patients per month for weight management.
- Prescribe anti-obesity medications (AOMs) to their patients they personally treat for weight management/obesity care; priority given to those who treat at least 10% of the patients they personally treat for weight management/obesity care with anti-obesity medications (AOMs).
- Prescribe injectable semaglutide for weight management.
- Be a specialty of interest (varies by country); mix of primary care, specialists such as Endocrinologists, Diabetologists, Nutrition Specialists, Obesity Specialists and others.
Who cannot join
- For an eligible participant (individuals initiated on injectable semaglutide for weight management), all exclusion criteria must be answered "no".
- Unwillingness or language barriers precluding adequate understanding or cooperation.
- Is currently or planning to become pregnant in next six months.
- Is taking injectable semaglutide for Type 2 diabetes management only.
- For an eligible participant (HCPs), all exclusion criteria must be answered "no".
- Prior participation in this study. Participation is defined as having given informed consent and submitting responses to an interview.
- Unwillingness or language barriers precluding adequate understanding or cooperation.
- Only treats patients under 18 years of age.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
The purpose of this study is to collect information for scientific research and to better understand the experiences of participants managing their weight. The study aims to collect valid responses through online interviews from participants. This study is a survey-based study without collection of laboratory data. Duration of the study will be about 14 months.
- Conditions
- Obesity
- Being tested
- No treatment given
- Medical subject headings
- Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No treatment givenOther
No treatment given
| Study group | Role | What they receive |
|---|---|---|
| Baseline | 0 - 8 weeks post-initiation, individuals who self-reported an initiation date as day, month and year combination that is no more than eight weeks prior to the date that they complete the screener to participate in the study. Receives: Other: No treatment given | |
| End of Escalation Phase | 16 - 24 weeks post-initiation, individuals who self-reported an initiation date as day, month and year combination that is at least 16 weeks but no more than 24 weeks prior to the date that they complete the screener to participate in the study. Receives: Other: No treatment given | |
| Weight Loss Phase | 48 - 56 weeks post-initiation, individuals who self-reported an initiation date as day, month and year combination that is at least 48 weeks but no more than 56 weeks prior to the date that they complete the screener to participate in the study Receives: Other: No treatment given | |
| Stable Weight Phase | More than or equal to (≥) 68 weeks post-initiation, individuals who self-reported an initiation date as day, month and year combination that is at least 68 weeks prior to the date that they complete the screener to participate in the study. Receives: Other: No treatment given | |
| Healthcare Providers (HCP)s | HCPs will be recruited from an opt-in panel available in each country which includes the practitioners representing different settings of obesity care. Qualified HCPs will be invited to participate in a one-on-one IDI with a moderator from each of the participating countries. Receives: Other: No treatment given |
What is being measured
The primary outcome is the main question the study is designed to answer.
Description of characteristics, including clinical, demographic and physical characteristics, among individuals initiated on injectable semaglutide for weight management
Patient Quantitative Segment Multi select from a defined list Single select from a defined list Numeric entry Open-ended type-in Patient Qualitative Segment Open-ended commentary
Measured: At the time of survey response (Day 1)
Description of the experience of individuals initiated on injectable semaglutide for weight management through personal perception of physical and mental health and self-reported QoL
Patient Quantitative Segment 7-point Likert scale for agreement (where 1 indicates extremely dissatisfied and 7 indicates extremely satisfied) Single select from a defined list EQ-5D-5L Patient Qualitative Segment Open-ended commentary
Measured: At the time of survey response (Day 1)
Individual-reported change in BMI since initiation
Patient Quantitative Segment Numeric entry (BMI calculated based on self-reported height and weight)
Measured: At the time of survey response (Day 1)
Individual-reported achievement of weight loss goal
Patient Quantitative Segment Yes/No; percentage of weight loss goal achieved Patient Qualitative Segment Open-ended commentary
Measured: At the time of survey response (Day 1)
Individual-reported change in weight since initiation
Patient Quantitative Segment Numeric entry in (kgs); percentage of weight change Patient Qualitative Segment Open-ended commentary
Measured: At the time of survey response (Day 1)
Individual-reported changes in daily life since initiation on injectable semaglutide
Patient Qualitative Segment Open-ended commentary
Measured: At the time of survey response (Day 1)
Secondary outcomes (32)
Treatment expectation of individuals initiated on injectable semaglutide of ability to achieve weight loss goal using injectable semaglutide
Patient Quantitative Segment 7-point Likert scale for agreement (where 1 indicates not at all confident and 7 indicates extremely confident) Patient Qualitative Segment Open-ended commentary
Measured: At the time of survey response (Day 1)
Expectation for length of time of treatment to desired result from date of initiation on injectable semaglutide at baseline
Patient Quantitative Segment Numeric entry months Patient Qualitative Segment Open-ended commentary
Measured: At the time of survey response (Day 1)
Expectation of individuals initiated on injectable semaglutide for weight management who believe they will have greater success in achieving their weight loss with the use of injectable semaglutide
Patient Quantitative Segment 7-point Likert scale for agreement (where 1 indicates strongly disagree and 7 indicates strongly agree) Patient Qualitative Segment Open-ended commentary
Measured: At the time of survey response (Day 1)
Expected benefits of injectable semaglutide
Patient Quantitative Segment Multi select from a defined list
Measured: At the time of survey response (Day 1)
Satisfaction with weight loss since initiation
Patient Quantitative Segment 7-point Likert scale for satisfaction (where 1 indicates extremely dissatisfied all and 7 indicates extremely satisfied) Patient Qualitative Segment Open-ended commentary
Measured: At the time of survey response (Day 1)
Overall satisfaction with injectable semaglutide
Patient Quantitative Segment 7-point Likert scale for satisfaction (where 1 indicates extremely dissatisfied all and 7 indicates extremely satisfied) Patient Qualitative Segment Open-ended commentary
Measured: At the time of survey response (Day 1)
Individual-reported changes in perception of injectable semaglutide since initiation
Patient Qualitative Segment Open-ended commentary
Measured: At the time of survey response (Day 1)
Attitudes of individuals related to obesity or weight related stigmatization or discrimination prior to/since/due to initiation on injectable semaglutide
Patient Quantitative Segment Multi select from a defined list
Measured: At the time of survey response (Day 1)
Attitudes of individuals initiated on injectable semaglutide for weight management related to obesity as a chronic disease
Patient Quantitative Segment 7-point Likert scale for agreement (where 1 indicates strongly disagree and 7 indicates strongly agree)
Measured: At the time of survey response (Day 1)
Attitudes of individuals initiated on injectable semaglutide for weight management related to weight loss being their responsibility
Patient Quantitative Segment 7-point Likert scale for agreement (where 1 indicates strongly disagree and 7 indicates strongly agree)
Measured: At the time of survey response (Day 1)
Attitudes of individuals initiated on injectable semaglutide for weight management related to weight loss being more likely with use of prescription medication for weight loss (AOMs)
Patient Quantitative Segment 7-point Likert scale for agreement (where 1 indicates strongly disagree and 7 indicates strongly agree)
Measured: At the time of survey response (Day 1)
Degree of knowledge of individuals initiated on injectable semaglutide for weight management related to how prescription weight loss medications (AOMs) work in the body
Patient Quantitative Segment 7-point Likert scale for agreement (where 1 indicates strongly disagree and 7 indicates strongly agree) Patient Qualitative Segment Open-ended commentary
Measured: At the time of survey response (Day 1)
Behaviours of individuals initiated on injectable semaglutide for weight management related to making lifestyle changes in addition to initiating on injectable semaglutide for weight loss or weight management to achieve their weight loss goals
Patient Quantitative Segment Multi select from a defined list Patient Qualitative Segment Open-ended commentary
Measured: At the time of survey response (Day 1)
Attitudes of individuals initiated injectable semaglutide for weight management related to the necessity to make lifestyle changes in addition to initiating injectable semaglutide for weight loss or weight management to achieve their weight loss goals
Patient Quantitative Segment 7-point Likert scale for agreement (where 1 indicates strongly disagree and 7 indicates strongly agree) Patient Qualitative Segment Open-ended commentary
Measured: At the time of survey response (Day 1)
Attitudes of individuals who initiated on injectable semaglutide for weight management relating to ease of maintaining lifestyle changes (e.g., eating a healthy diet and getting regular exercise) since initiating on injectable semaglutide
Patient Quantitative Segment 7-point Likert scale for agreement (where 1 indicates strongly disagree and 7 indicates strongly agree)
Measured: At the time of survey response (Day 1)
Individual-reported change in overall knowledge of how AOMs work from initiation on injectable semaglutide to present day
Patient Quantitative Segment 7-point Likert scale for agreement (where 1 indicates strongly disagree and 7 indicates strongly agree)
Measured: At the time of survey response (Day 1)
Attitudes related to viewing obesity as a chronic disease
HCP Qualitative Segment 7-point Likert scales for agreement (where 1 indicates strongly disagree and 7 indicates strongly agree) Open-ended commentary
Measured: At the time of survey response (Day 1)
Attitudes related to belief weight loss is solely an individual's responsibility
HCP Qualitative Segment 7-point Likert scales for agreement (where 1 indicates strongly disagree and 7 indicates strongly agree) Open-ended commentary
Measured: At the time of survey response (Day 1)
Attitudes related to belief weight loss requires use of prescription medication for weight loss (AOMs)
HCP Qualitative Segment 7-point Likert scales for agreement (where 1 indicates strongly disagree and 7 indicates strongly agree) Open-ended commentary
Measured: At the time of survey response (Day 1)
Attitudes related to belief individuals must make lifestyle changes in addition to initiating on injectable semaglutide for weight loss or weight management to achieve their weight loss goals
HCP Qualitative Segment 7-point Likert scales for agreement (where 1 indicates strongly disagree and 7 indicates strongly agree) Open-ended commentary
Measured: At the time of survey response (Day 1)
Attitudes related to belief individuals will have greater success in achieving their weight loss goals with use of injectable semaglutide
HCP Qualitative Segment 7-point Likert scales for agreement (where 1 indicates strongly disagree and 7 indicates strongly agree) Open-ended commentary
Measured: At the time of survey response (Day 1)
Attitudes related to level of comfort prescribing AOMs and injectable semaglutide specifically for weight management
HCP Qualitative Segment 7-point Likert scales for agreement (where 1 indicates strongly disagree and 7 indicates strongly agree) Open-ended commentary
Measured: At the time of survey response (Day 1)
Reasons for length of adherence
Patient Quantitative Segment Multi select from a defined list Patient Qualitative Segment Open-ended commentary
Measured: At the time of survey response (Day 1)
Future planned use of injectable semaglutide (among current users)
Patient Quantitative Segment Multi select from a defined list; Numeric entry months Patient Qualitative Segment Open-ended commentary
Measured: At the time of survey response (Day 1)
Reasons for discontinuation (among those who discontinued)
Patient Quantitative Segment Multi select from a defined list Patient Qualitative Segment Open-ended commentary
Measured: At the time of survey response (Day 1)
Likelihood to resume injectable semaglutide (specifically for weight management) after formal discontinuation and reasons
Patient Quantitative Segment 7-point Likert scale for likelihood (where 1 indicates not at all likely and 7 indicates extremely likely) Multi select from a defined list Patient Qualitative Segment Open-ended commentary
Measured: At the time of survey response (Day 1)
Individual-reported likelihood of continuation on injectable semaglutide until achieve goal weight and reasons
Patient Quantitative Segment 7-point Likert scale for likelihood (where 1 indicates not at all likely and 7 indicates extremely likely)
Measured: At the time of survey response (Day 1)
Likelihood of continuation on injectable semaglutide after achieving weight loss goal and reasons
Patient Quantitative Segment 7-point Likert scale for likelihood (where 1 indicates not at all likely and 7 indicates extremely likely)
Measured: At the time of survey response (Day 1)
Treatment pause initiated by individual and reasons
Patient Quantitative Segment Yes/No; Numeric entry; Multi select from a defined list Patient Qualitative Segment Open-ended commentary
Measured: At the time of survey response (Day 1)
Treatment pause initiated by HCP and reasons
Patient Quantitative Segment Yes/No; Numeric entry; Multi select from a defined list Patient Qualitative Segment Open-ended commentary
Measured: At the time of survey response (Day 1)
Number of treatment pauses
Patient Quantitative Segment Numeric entry
Measured: At the time of survey response (Day 1)
Among those with low likelihood to use injectable semaglutide after discontinuation, potential use of another AOM
Patient Quantitative Segment Yes/No/Not Sure
Measured: At the time of survey response (Day 1)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Sep 2025
- Study start26 Sep 2025
- Primary completion30 Sep 2026 (estimated)
- Study completion30 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ObesityStudies of the same condition, open and under way.
- More trials run by Novo Nordisk A/SThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 2,546 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Transparency (dept. 2834), Study director, Novo Nordisk A/S
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07154238
- Sponsor's protocol ID
- NN9536-8412
- Other IDs
- U1111-1314-6149
- Acronym
- OUTSTEP-1
- Status last verified
- Nov 2025
- First submitted
- 26 Aug 2025
- Last updated
- 25 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Study at a glance
From the registry record, last updated by the sponsor on 25 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.
- ClinicalTrials.gov ID
- NCT07154238
- Acronym / sponsor ID
- OUTSTEP-1 / NN9536-8412
- Conditions
- Obesity
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 2,546 participants (estimated)
- Lead sponsor
- Novo Nordisk A/SIndustry (pharma, biotech, devices)
- Study start
- 26 Sep 2025 (actual)
- Primary completion
- 30 Sep 2026 (estimated)
- Study completion
- 30 Sep 2026 (estimated)
- First posted
- 4 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to collect information for scientific research and to better understand the experiences of participants managing their weight. The study aims to collect valid responses through online interviews from participants. This study is a survey-based study without collection of laboratory data. Duration of the study will be about 14 months.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| Baseline | – | Other: No treatment given0 - 8 weeks post-initiation, individuals who self-reported an initiation date as day, month and year combination that is no more than eight weeks prior to the date that they complete the screener to participate in the study. |
| End of Escalation Phase | – | Other: No treatment given16 - 24 weeks post-initiation, individuals who self-reported an initiation date as day, month and year combination that is at least 16 weeks but no more than 24 weeks prior to the date that they complete the screener to participate in the study. |
| Weight Loss Phase | – | Other: No treatment given48 - 56 weeks post-initiation, individuals who self-reported an initiation date as day, month and year combination that is at least 48 weeks but no more than 56 weeks prior to the date that they complete the screener to participate in the study |
| Stable Weight Phase | – | Other: No treatment givenMore than or equal to (≥) 68 weeks post-initiation, individuals who self-reported an initiation date as day, month and year combination that is at least 68 weeks prior to the date that they complete the screener to participate in the study. |
| Healthcare Providers (HCP)s | – | Other: No treatment givenHCPs will be recruited from an opt-in panel available in each country which includes the practitioners representing different settings of obesity care. Qualified HCPs will be invited to participate in a one-on-one IDI with a moderator from each of the participating countries. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- This study will collect quantitative and qualitative data from individuals treated with injectable semaglutide for weight management in real-world settings. The study will include two groups of participants: 1. Individuals who belong to or are recruited to an opt-in panel in the countries of interest and who have initiated injectable semaglutide for weight management. They will be classified according to the time when they first initiated treatment with injectable semaglutide for weight management. 2. HCPs who prescribe injectable semaglutide for weight management will be recruited from an existing opt-in panel in the countries of interest.
Key inclusion criteria (13 listed)
- For an eligible participant (individuals initiated on injectable semaglutide for weight management), all inclusion criteria must be answered "yes".
- For an eligible participant (HCPs), all inclusion criteria must be answered "yes".
Key exclusion criteria (8 listed)
- For an eligible participant (individuals initiated on injectable semaglutide for weight management), all exclusion criteria must be answered "no".
- For an eligible participant (HCPs), all exclusion criteria must be answered "no".
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No treatment givenNo treatment given | Other | Baseline, End of Escalation Phase, Healthcare Providers (HCP)s, Stable Weight Phase, Weight Loss Phase |
Primary outcome
Description of characteristics, including clinical, demographic and physical characteristics, among individuals initiated on injectable semaglutide for weight management
Time frame: At the time of survey response (Day 1)
Patient Quantitative Segment Multi select from a defined list Single select from a defined list Numeric entry Open-ended type-in Patient Qualitative Segment Open-ended commentary
Description of the experience of individuals initiated on injectable semaglutide for weight management through personal perception of physical and mental health and self-reported QoL
Time frame: At the time of survey response (Day 1)
Patient Quantitative Segment 7-point Likert scale for agreement (where 1 indicates extremely dissatisfied and 7 indicates extremely satisfied) Single select from a defined list EQ-5D-5L Patient Qualitative Segment Open-ended commentary
Individual-reported change in BMI since initiation
Time frame: At the time of survey response (Day 1)
Patient Quantitative Segment Numeric entry (BMI calculated based on self-reported height and weight)
Individual-reported achievement of weight loss goal
Time frame: At the time of survey response (Day 1)
Patient Quantitative Segment Yes/No; percentage of weight loss goal achieved Patient Qualitative Segment Open-ended commentary
Individual-reported change in weight since initiation
Time frame: At the time of survey response (Day 1)
Patient Quantitative Segment Numeric entry in (kgs); percentage of weight change Patient Qualitative Segment Open-ended commentary
Individual-reported changes in daily life since initiation on injectable semaglutide
Time frame: At the time of survey response (Day 1)
Patient Qualitative Segment Open-ended commentary
32 secondary outcomes
Treatment expectation of individuals initiated on injectable semaglutide of ability to achieve weight loss goal using injectable semaglutide
Time frame: At the time of survey response (Day 1)
Expectation for length of time of treatment to desired result from date of initiation on injectable semaglutide at baseline
Time frame: At the time of survey response (Day 1)
Expectation of individuals initiated on injectable semaglutide for weight management who believe they will have greater success in achieving their weight loss with the use of injectable semaglutide
Time frame: At the time of survey response (Day 1)
Expected benefits of injectable semaglutide
Time frame: At the time of survey response (Day 1)
Satisfaction with weight loss since initiation
Time frame: At the time of survey response (Day 1)
Overall satisfaction with injectable semaglutide
Time frame: At the time of survey response (Day 1)
Individual-reported changes in perception of injectable semaglutide since initiation
Time frame: At the time of survey response (Day 1)
Attitudes of individuals related to obesity or weight related stigmatization or discrimination prior to/since/due to initiation on injectable semaglutide
Time frame: At the time of survey response (Day 1)
Attitudes of individuals initiated on injectable semaglutide for weight management related to obesity as a chronic disease
Time frame: At the time of survey response (Day 1)
Attitudes of individuals initiated on injectable semaglutide for weight management related to weight loss being their responsibility
Time frame: At the time of survey response (Day 1)
Attitudes of individuals initiated on injectable semaglutide for weight management related to weight loss being more likely with use of prescription medication for weight loss (AOMs)
Time frame: At the time of survey response (Day 1)
Degree of knowledge of individuals initiated on injectable semaglutide for weight management related to how prescription weight loss medications (AOMs) work in the body
Time frame: At the time of survey response (Day 1)
Behaviours of individuals initiated on injectable semaglutide for weight management related to making lifestyle changes in addition to initiating on injectable semaglutide for weight loss or weight management to achieve their weight loss goals
Time frame: At the time of survey response (Day 1)
Attitudes of individuals initiated injectable semaglutide for weight management related to the necessity to make lifestyle changes in addition to initiating injectable semaglutide for weight loss or weight management to achieve their weight loss goals
Time frame: At the time of survey response (Day 1)
Attitudes of individuals who initiated on injectable semaglutide for weight management relating to ease of maintaining lifestyle changes (e.g., eating a healthy diet and getting regular exercise) since initiating on injectable semaglutide
Time frame: At the time of survey response (Day 1)
Individual-reported change in overall knowledge of how AOMs work from initiation on injectable semaglutide to present day
Time frame: At the time of survey response (Day 1)
Attitudes related to viewing obesity as a chronic disease
Time frame: At the time of survey response (Day 1)
Attitudes related to belief weight loss is solely an individual's responsibility
Time frame: At the time of survey response (Day 1)
Attitudes related to belief weight loss requires use of prescription medication for weight loss (AOMs)
Time frame: At the time of survey response (Day 1)
Attitudes related to belief individuals must make lifestyle changes in addition to initiating on injectable semaglutide for weight loss or weight management to achieve their weight loss goals
Time frame: At the time of survey response (Day 1)
Attitudes related to belief individuals will have greater success in achieving their weight loss goals with use of injectable semaglutide
Time frame: At the time of survey response (Day 1)
Attitudes related to level of comfort prescribing AOMs and injectable semaglutide specifically for weight management
Time frame: At the time of survey response (Day 1)
Reasons for length of adherence
Time frame: At the time of survey response (Day 1)
Future planned use of injectable semaglutide (among current users)
Time frame: At the time of survey response (Day 1)
Reasons for discontinuation (among those who discontinued)
Time frame: At the time of survey response (Day 1)
Likelihood to resume injectable semaglutide (specifically for weight management) after formal discontinuation and reasons
Time frame: At the time of survey response (Day 1)
Individual-reported likelihood of continuation on injectable semaglutide until achieve goal weight and reasons
Time frame: At the time of survey response (Day 1)
Likelihood of continuation on injectable semaglutide after achieving weight loss goal and reasons
Time frame: At the time of survey response (Day 1)
Treatment pause initiated by individual and reasons
Time frame: At the time of survey response (Day 1)
Treatment pause initiated by HCP and reasons
Time frame: At the time of survey response (Day 1)
Number of treatment pauses
Time frame: At the time of survey response (Day 1)
Among those with low likelihood to use injectable semaglutide after discontinuation, potential use of another AOM
Time frame: At the time of survey response (Day 1)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Nov 2025.
- Individual participant dataSharing planned: Yes. According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Related trials for Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Clinical Transparency (dept. 2834) study director
Novo Nordisk A/S
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Obesity, run by Novo Nordisk A/S at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 25 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Description of characteristics, including clinical, demographic and physical characteristics, among individuals initiated on injectable semaglutide for weight management (time frame: At the time of survey response (Day 1)). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Nov 2025.